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Abstract
Purpose To determine serum 25(OH)D and 1,25(OH)2D relationship with hepatitis B vaccination (study 1). Then, to inves-
tigate the effects on hepatitis B vaccination of achieving vitamin D sufficiency (serum 25(OH)D ≥ 50 nmol/L) by a unique 
comparison of simulated sunlight and oral vitamin  D3 supplementation in wintertime (study 2).
Methods Study 1 involved 447 adults. In study 2, 3 days after the initial hepatitis B vaccination, 119 men received either 
placebo, simulated sunlight (1.3 × standard-erythema dose, 3 × /week for 4 weeks and then 1 × /week for 8 weeks) or oral 
vitamin  D3 (1000 IU/day for 4 weeks and 400 IU/day for 8 weeks). We measured hepatitis B vaccination efficacy as percent-
age of responders with anti-hepatitis B surface antigen immunoglobulin G ≥ 10 mIU/mL.
Results In study 1, vaccine response was poorer in persons with low vitamin D status (25(OH)D ≤ 40 vs 41–71 nmol/L mean 
difference [95% confidence interval] − 15% [− 26, − 3%]; 1,25(OH)2D ≤ 120 vs ≥ 157 pmol/L − 12% [− 24%, − 1%]). Vac-
cine response was also poorer in winter than summer (− 18% [− 31%, − 3%]), when serum 25(OH)D and 1,25(OH)2D were 
at seasonal nadirs, and 81% of persons had serum 25(OH)D < 50 nmol/L. In study 2, vitamin D supplementation strategies 
were similarly effective in achieving vitamin D sufficiency from the winter vitamin D nadir in almost all (~ 95%); however, 
the supplementation beginning 3 days after the initial vaccination did not effect the vaccine response (vitamin D vs placebo 
4% [− 21%, 14%]).
Conclusion Low vitamin D status at initial vaccination was associated with poorer hepatitis B vaccine response (study 
1); however, vitamin D supplementation commencing 3 days after vaccination (study 2) did not influence the vaccination 
response.
Clinical trial registry number Study 1 NCT02416895; https ://clini caltr ials.gov/ct2/show/study /NCT02 41689 5; Study 2 
NCT03132103; https ://clini caltr ials.gov/ct2/show/NCT03 13210 3.
Keywords Cholecalciferol · Vitamin D · 25-Hydroxyvitamin D · Hepatitis B · Vaccination · UVB
Introduction
Discovery of the vitamin D receptor in almost all immune 
cells, and the many roles vitamin D has in innate and adap-
tive arms of immunity [1–3], highlight the importance of 
vitamin D in the regulation of immune responses [4]. As 
such, avoiding low serum 25-hydroxyvitamin D (25(OH)D) 
and achieving vitamin D sufficiency (25(OH)D ≥ 50 nmol/L) 
may be important for the development of vaccine responses 
and consequently public health [5]. Cell and animal stud-
ies indicate that vitamin D may modulate vaccine responses 
through 1,25-dihydroxyvitamin D (1,25(OH)2D) interaction 
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with antigen presentation [6], dendritic cell migration, and 
the subsequent activation of T and B cell antibody responses 
[7–9]. Indeed, vitamin D supplementation that corrected 
wintertime vitamin D status to achieve sufficiency before 
a tetanus toxoid booster vaccination resulted in higher IgG 
antibody concentration compared to a placebo [10].
The influence of vitamin D on the development of the 
hepatitis B vaccination response in humans remains unclear; 
previous investigations have only studied chronic kidney 
patients and report conflicting findings [11, 12]. Moreo-
ver, the relationship between the biologically active form 
of vitamin D, 1,25(OH)2D, and hepatitis B vaccine is yet to 
be examined. Hepatitis B vaccination has previously been 
shown to be influenced by genetics and lifestyle factors 
[13–15] with 10–15% of adults responding inadequately by 
producing too few antibodies, as dictated by an anti-hepatitis 
B surface antigen immunoglobulin G (IgG) concentration 
of less than 10 mIU/mL [16]. Conversely, those respond-
ing to the vaccination with IgG concentration of 10 mIU/
mL or more are generally accepted to be protected against 
infection clinically [16, 17]. Whether vitamin D influences 
the development of hepatitis B vaccination in healthy adults 
is unknown, but important to understand given that more 
than 50% fail to achieve vitamin D sufficiency during win-
ter months [18–20]; and many adults remain unvaccinated 
because childhood vaccine coverage is ~ 90% or less and 
routine infant hepatitis B vaccination began only recently in 
some countries (e.g., UK [21–23]). The hepatitis B vaccina-
tion course presents a suitable model to study the influence 
of vitamin D on the secondary immune response because 
there is widespread inter-individual variability in the mag-
nitude of the antibody response after the second vaccination, 
and it is more possible to control prior exposure than with 
other commonly experienced vaccines (e.g., influenza) [24].
Here, we present results from two studies examining the 
influence of vitamin D on hepatitis B vaccine response. 
In these studies, we measured 1,25(OH)2D, vitamin D’s 
biologically active form, and 25(OH)D, which with their 
respective 4–6-h and 2–3-week half lives can be consid-
ered acute and chronic vitamin D status markers, respec-
tively [25]. In study 1, a prospective cohort study of 447 
healthy young men and women conducted during all sea-
sons, we examined for the first time serum 1,25(OH)2D 
and 25(OH)D relationship with hepatitis B vaccina-
tion in healthy adults. We hypothesized that low serum 
1,25(OH)2D and 25(OH)D at the time of initial vaccina-
tion would be associated with poorer secondary antibody 
response to hepatitis B vaccination. In study 2, a rand-
omized placebo-controlled trial, we determined the effect 
of 12-week wintertime vitamin D supplementation on the 
hepatitis B vaccination response. The supplementation was 
a unique comparison of simulated sunlight in accordance 
with recommendations on safe (non-sunburning), low-level 
sunlight exposure [26], and oral vitamin  D3 to achieve vita-
min D sufficiency (serum 25(OH)D ≥ 50 nmol/L). Vitamin 
D sufficiency was targeted as maintaining serum 25(OH)
D concentration ≥ 50 nmol/L has been recommended for 
multiple health outcomes [27] by the Institute of Medicine 
(IOM) and European Food Safety Authority (EFSA) and 
is achievable using safe doses [19, 20]. The comparison 
was also made as vitamin D can be obtained from dietary 
sources but is predominately synthesized by skin exposure 
to solar ultraviolet (UV) B radiation; UV radiation has a 
range of vitamin D-dependent and -independent effects on 
immunity [28, 29]. We hypothesized that vitamin D sup-
plementation that achieves vitamin D sufficiency during 
winter when vitamin D status is usually low would lead to 
superior secondary antibody response to hepatitis B vac-
cination compared to placebo supplementation.
Methods
The Ministry of Defence (UK) Research Ethics Commit-
tee approved these studies, and protocols were conducted 
in accordance with the Declaration of Helsinki (2013). All 
participants provided written informed consent.
Study 1
Participant recruitment, inclusion and exclusion criteria
Between June 2014 and November 2015, 1268 men and 
women who entered the British Army were assessed for 
eligibility for this prospective cohort study. Eligible partici-
pants were ≥ 18 years of age. One thousand one hundred and 
three recruits volunteered (men from the Infantry Training 
Centre, Catterick, UK; latitude 54° N, and women from the 
Army Training Centre, Pirbright, UK; latitude 51° N). Par-
ticipants were excluded from the final analysis if they failed 
the initial medical assessment, followed an atypical hepatitis 
B vaccination schedule (the first two vaccine doses were 
not administered within 4 weeks of each other), or did not 
provide a blood sample to assess the secondary hepatitis 
B vaccine response. Participants were also excluded from 
statistical analysis if their medical records documented 
previous exposure to hepatitis B vaccination; or, if this 
was later confirmed by measurable antibody titers against 
hepatitis B surface antigen detected in baseline samples 
(anti-HBs titers > 0 mIU/mL). The baseline demographics, 
anthropometrics, and lifestyle behaviors for the 447 par-
ticipants included in the final analysis are summarized in 
Table 1 (Supplemental Table 1 includes details of the larger 
recruited sample).
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Procedures
Before participants commenced Basic Military training, 
they completed an initial medical assessment. During the 
initial medical assessment, participants received their first 
20-μg dose of recombinant hepatitis B vaccine into the del-
toid muscle (Engerix-B, Smithkline Beecham Pharmaceu-
ticals, Uxbridge, UK) and a venous blood sample was col-
lected for the determination of hepatitis B antibody titer, 
serum 25(OH)D and 1,25(OH)2D concentrations (Fig. 1). 
At the initial medical assessment, we also collected base-
line measures of participant demographics (e.g., ethnicity) 
and anthropometrics; height and body mass were assessed 
in light clothing with shoes removed by stadiometer and 
digital platform scale, respectively (SECA 703, Birming-
ham, UK). Lifestyle factors previously shown to influence 
the vaccination response were also assessed by question-
naire; including alcohol and smoking use, sleep and mood 
[13–15]. To assess sleep duration and quality the night 
before vaccination participants completed a questionnaire 
based on the procedures of Prather et al. [15]. Sleep dura-
tion was calculated as the number of hours and minutes 
elapsed between the time they reported going to sleep 
and the time they reported waking. Sleep quality was 
reported on a scale from 1 = very poor to 4 = very good. 
Before receiving their initial hepatitis B vaccination, par-
ticipants also completed a Brunel mood scale (BRUMS) 
Table 1  Study 1 baseline 
participant demographics, 
anthropometrics, lifestyle 
behaviors, sleep, mood and 
all-cause illness in cohorts 
recruited across seasons
Values presented as mean ± SD, unless otherwise stated
COCP combined oral contraceptive pill, POP progesterone-only pill
*P < 0.05 lower than autumn
a Female contraception data collected from a female specific questionnaire (n = 37 excluded from final data 
analysis)
b Greater scores indicate a greater feeling of the mood (maximum per mood = 20)
c Physician diagnosed cases of respiratory and gastrointestinal tract infection
All n = 447 Winter Spring Summer Autumn
n = 88 n = 63 n = 115 n = 181
Demographics
 Age (years) 21.7 ± 3.0 21.5 ± 3.0 22.1 ± 3.2 21.9 ± 3.0 21.5 ± 3.1
 Ethnicity, Caucasian [n (%)] 434 (97) 85 (97) 62 (98) 109 (96) 178 (98)
Anthropometrics
 Height (m) 1.73 ± 0.08 1.73 ± 0.09 1.71 ± 0.09 1.75 ± 0.08 1.71 ± 0.08
 Body mass (kg) 71.8 ± 10.8 72.1 ± 11.3 70.8 ± 10.8 74.0 ± 10.7 70.5 ± 10.5
 BMI (kg/m2) 24.0 ± 2.7 23.9 ± 2.8 24.2 ± 2.7 24.1 ± 2.6 23.9 ± 2.7
Lifestyle behaviors
 Alcohol user, [n (%)] 376 (88) 76 (93) 50 (82) 99 (87) 151 (88)
 Smoker, [n (%)] 259 (58) 53 (61) 38 (60) 71 (62) 97 (54)
Sleep night before initial vaccination
 Duration (h) 6.4 ± 0.8 6.3 ± 0.7 6.4 ± 0.5 6.3 ± 0.9 6.6 ± 0.9
 Quality (very poor = 1 to very good = 4) 1.7 ± 0.8 1.7 ± 0.8 1.6 ± 0.7 1.8 ± 0.8 1.6 ± 0.8
Contraception (n = 138)a
 None, [n (%)] 36 (26) 7 (19) 4 (11) 5 (14) 20 (56)
 COCP, [n (%)] 50 (36) 9 (18) 15 (30) 5 (10) 21 (42)
 POP, [n (%)] 9 (7) 2 (22) 2 (22) 1 (11) 4 (45)
 Injection, [n (%)] 8 (6) 2 (25) 0 (0) 1 (12) 5 (63)
 Implant, [n (%)] 35 (25) 9 (26) 6 (17) 5 (14) 15 (43)
Mood before initial  vaccinationb
 Vigor 8.4 ± 3.0 8.5 ± 3.0 7.3 ± 3.1 8.6 ± 2.8 8.7 ± 3.1
 Anger 0.9 ± 1.6 0.6 ± 1.1 0.7 ± 1.5 1.0 ± 1.6 0.9 ± 1.7
 Tension 4.8 ± 3.4 4.1 ± 3.1 4.7 ± 3.7 4.3 ± 3.1 5.3 ± 3.5
 Confusion 2.3 ± 2.4 2.4 ± 2.8 1.8 ± 1.9 2.5 ± 2.4 2.3 ± 2.5
 Depression 0.7 ± 1.6 0.6 ± 1.1 0.6 ± 2.0 0.7 ± 1.3 0.8 ± 1.7
 Fatigue 4.2 ± 3.0 3.6 ± 2.9 4.3 ± 3.3 4.2 ± 2.8 4.4 ± 3.0
All-cause illness [n (%)]c 71 (16) 8 (9)* 10 (16) 10 (9)* 43 (24)
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[30], which measures 6 moods (vigor, anger, tension, 
confusion, depression, fatigue). Each mood is assessed by 
4 items scored from 0 = not at all to 4 = extremely and, 
therefore, the maximum score per mood is 20, with greater 
scores indicating a greater feeling of the mood. In line 
with the typical hepatitis B vaccination schedule, partici-
pants received a second 20-μg hepatitis B vaccine dose 
1 month after the first. A second venous blood sample 
was collected 8 weeks after the second hepatitis B vaccine 
dose (3 months after the first hepatitis B vaccine dose) to 
determine secondary serum hepatitis B antibody titers, the 
primary outcome measure. The serum hepatitis B antibody 
titer (anti-HBs) was assessed as this is the routine sero-
logical test to determine if a person has been successfully 
vaccinated against hepatitis B [16]. We focused on the 
antibody response to the second vaccination because there 
is widespread inter-individual variability in the magnitude 
of antibody response following the second vaccination of 
the typical three-dose series [24]. This variability is in 
distinct contrast with the antibody response to the first vac-
cination, when < 10% of individuals have detectable levels 
of antibody, or the third, when the majority of individuals 
have mounted maximal antibody responses, respectively 
[15]. ‘All-cause illness’ consisting of physician diagnosed 
cases of upper and lower respiratory tract infection and 
gastrointestinal infection were also retrieved from medical 
records for the period of basic training.
Study 2
Participant recruitment and exclusion criteria
Healthy men were recruited in a double-blind randomized, 
placebo-controlled trial upon entering the British Army 
Combat Infantryman’s Course, Catterick, UK during Janu-
ary and February of 2016 and 2017, when ambient UVB is 
negligible at UK latitudes (50–60° N), and serum 25(OH)
D is at a seasonal low. Eligible participants were ≥ 17 years 
of age and had passed the initial medical assessment; had 
no history of skin cancer, photosensitivity, or lupus erythe-
matosus; and had sun-reactive skin types I–IV [31]. Partici-
pants were excluded for the same reasons as in study 1, plus 
current consumption of vitamin D in dietary supplements; 
use of a sunbed or travel to a sunny climate 3 months before 
the study.
Experimental procedures
Participants had the same baseline assessments and hepatitis 
B vaccination schedule as study 1 (Fig. 1). Following this, 
we block randomized participants within their platoons to 
one of the four intervention groups: (1) solar-simulated radi-
ation (SSR); (2) solar-simulated radiation placebo (SSR-P); 
(3) oral vitamin  D3 (ORAL); or (4) oral placebo (ORAL-P). 
Block randomization by randomizer.org resulted in an equal 
distribution of intervention groups within each platoon, and 










3-times-a-week SSR or placebo once-a-week
ORAL/
ORAL-P
1,000 IU/day oral 
vitamin D3 or 
placebo
400 IU/day oral vitamin D3 or placebo
Weeks
Fig. 1  Schematic of study 1 and 2 procedures. Study 1 investigated 
the influence of vitamin D status at the time of the initial hepatitis B 
vaccination on the secondary antibody response to hepatitis B vac-
cination. Study 2 investigated the effect of vitamin D supplementation 
by solar-simulated radiation (SSR), oral vitamin  D3 (ORAL), or pla-
cebo (SSR-P or ORAL-P) after the initial hepatitis B vaccination on 
secondary hepatitis B vaccine response. Needle and bottle icon repre-
sents hepatitis B vaccination doses. Blood tube icon represents when 
blood samples were obtained for serum 25(OH)D, 1,25(OH)2D and 
hepatitis B antibody titer measurements
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ensured any differences in training conditions between pla-
toons did not influence the study outcomes. An independent 
researcher completed the randomization and investigators 
were blind to the randomization until statistical analyses 
were completed. The interventions began 3 days after the 
initial hepatitis B vaccine dose. The intervention strategy for 
the SSR and ORAL groups was to restore and then maintain 
vitamin D sufficiency (serum 25(OH)D ≥ 50 nmol/L) as rec-
ommended by Institute of Medicine (IOM) and the European 
Food Safety Authority (EFSA) [19, 20]. Participants com-
pleted a 4-week restoration phase, necessary because serum 
25(OH)D was at its winter nadir, followed by an 8-week 
maintenance phase (Fig. 1). Blood samples were obtained at 
baseline, and after 5 and 12 weeks for the determination of 
serum 25(OH)D and 1,25(OH)2D (Fig. 1). Vitamin D from 
solar UV radiation exposure was estimated in weeks 4 and 
11 using polysulphone badges and from the diet in week 12 
using a food frequency questionnaire [32]. On completion 
of the study, participants completed an ‘exit survey’, which 
required them to guess the intervention they thought they 
had been receiving.
Simulated sunlight intervention
In accordance with guidelines on safe, low-level sunlight 
exposure for vitamin D synthesis [26], and as described 
previously to achieve vitamin D sufficiency (serum 25(OH)
D ≥ 50 nmol/L) in the majority of white-skinned persons 
[33], those assigned to the SSR intervention were exposed 
three-times-a-week, during the restoration phase to an inves-
tigator-controlled constant UV radiation dose using a whole-
body irradiation cabinet (Hapro Jade, Kapelle, The Nether-
lands) fitted with Arimed B fluorescent tubes (Cosmedico, 
Stuttgart, Germany). The fluorescent tubes emitted a UV 
radiation spectrum similar to sunlight (λ 290–400 nm; 95% 
UVA 320–400 nm, 5% UVB 290–320 nm) that was charac-
terized by a spectroradiometer (USB2000 +, Ocean Optics 
BV, Duiven, The Netherlands) radiometrically calibrated 
with traceability to UK national standards. During each 
exposure, participants received a 1.3 standard erythemal 
dose (SED), and wore shorts and a T-shirt to expose ~ 40% of 
skin surface area. This dose is equivalent to ~ 15-min midday 
summer sun exposure in northern England (latitude 53.5° N) 
[33] and taking account of pre-vitamin D irradiance at differ-
ent latitudes, can be related to exposure times at other world 
locations [34]. For example, the equivalent exposure time in 
Philadelphia, Pennsylvania, USA (40° N) would be ~ 12 min; 
and that for Oslo, Norway (60° N) would be ~ 18 min. Dur-
ing the maintenance phase, we exposed SSR participants to 
the same 1.3 × SED dose only once-a-week: pilot investiga-
tions confirmed the required dose to maintain sufficiency 
(serum 25(OH)D ≥ 50 nmol/L). A constant SSR dose was 
maintained during the study by monitoring irradiance using 
a spectroradiometer (USB2000 +, Ocean Optics BV) and 
adjusting for any decrease in measured irradiance emitted by 
increasing exposure time (mean duration of SSR exposures 
was 229 ± 17 s). We controlled the exposure time using an 
electronic timer. Participants undergoing SSR-P treatment 
received the same number of intervention exposures each 
week and the exposure duration as SSR except the irradia-
tion cabinet fluorescent tubes were covered with transparent 
UV radiation blocking film (DermaGard UV film, SunGard, 
Woburn, Massachusetts, USA) [35] in a manner invisible to 
the participants and experimenters. Spectroradiometry con-
firmed that the UV radiation blocking film was effective at 
preventing transmission of 99.9% of UV radiation.
Oral vitamin  D3 intervention
Participants receiving the ORAL intervention consumed a 
daily vitamin  D3 supplement containing 1000 IU and 400 IU 
vitamin  D3 during the restoration phase and maintenance 
phase, respectively (Pure Encapsulations, Sudbury, Mas-
sachusetts, USA) [35]. The restoration dose (1000 IU/day) 
was based on previous predictive modeling to achieve serum 
25(OH)D ≥ 50 nmol/L [36], and pilot investigations that 
showed it achieved similar serum 25(OH)D concentrations 
to SSR; and was less than the tolerable upper intake recom-
mended by IOM and EFSA [19, 20]. The ORAL mainte-
nance dose (400 IU/day) was in accordance with recommen-
dations [19]. For 12 weeks, ORAL-P participants consumed 
a daily oral cellulose placebo capsule, identical in size, shape 
and color to the vitamin  D3 capsules (Almac Group, County 
Armagh, UK). Independent analysis found the vitamin  D3 
content of the 1000 and 400 IU capsules to be 1090 and 
460 IU, respectively and confirmed that the placebo did not 
contain vitamin D (NSF International Laboratories, Ann 
Arbor, Michigan, USA).
Biochemical analyses (study 1 and 2)
Whole blood samples were collected by venepuncture 
from an antecubital vein into plain vacutainer tubes (Bec-
ton–Dickinson, Oxford, UK) and left to clot for 1 h. Sub-
sequently, samples were centrifuged at 1500g for 10 min at 
4 °C and the serum aliquoted into Eppendorf tubes before 
being immediately frozen at − 80 °C for later analysis. Base-
line and secondary serum antibody titers were determined 
using a hepatitis B antibody enzyme-linked immunoassay 
kit (DiaSorin, Saluggia, Italy). The intra-assay coefficient 
of variation was 4.9% (study 1) and 5.9% (study 2). Total 
serum 25(OH)D was measured with high-pressure liquid 
chromatography–tandem mass spectrometry [37]; and serum 
1,25(OH)2D using the DiaSorin LIAISON XL 1,25(OH)2D 
chemiluminescent immunoassay (Stillwater, Minnesota, 
USA) method. Analyses were performed in a Vitamin D 
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External Quality Assurance Scheme certified laboratory 
(Bioanalytical Facility, University of East Anglia, Norwich, 
UK).
Statistical analysis
Secondary antibody titers have a non-normal distribution 
and, therefore, in line with the previous research [17], we 
categorized the development of secondary antibody response 
to the hepatitis B vaccine as the percentage of participants 
with serum antibody titer response to hepatitis B ≥ 10 mIU/
mL. Those participants with anti-HBs titers ≥ 10 mIU/mL 
were categorized as vaccine ‘responders’; whilst, those with 
antibody titers < 10 mIU/mL were categorized as vaccine 
‘non-responders’ [17]. Further, those responding to the vac-
cination with anti-HBs titers of 10 mIU/mL or more are 
generally accepted to be protected against infection clinically 
[16, 17]. The sample size estimation for study 1 and 2 was 
calculated as a minimum of 152, using the anticipated differ-
ence in hepatitis B vaccine responder rate of 20% (Cohen’s 
h = 0.4; small–medium effect size) between individuals dis-
playing low and high vitamin D status [11], with a type 1 
error (one tailed) of 5%, and a power of 80%. For study 1, 
we used Chi square analysis to compare the percentage of 
hepatitis B vaccine responders in those with IOM-defined 
vitamin D sufficient status (serum 25(OH)D ≥ 50 nmol/L) 
compared to those with serum < 50 nmol/L. However, as 
there is no consensus to the optimal vitamin D threshold 
for immune function [18, 38], we conducted Kruskal–Wal-
lis tests to compare the percentage of hepatitis B vaccine 
responders across 25(OH)D, 1,25(OH)2D and 24,25(OH)2D 
terciles. One-way ANOVA and Kruskal–Wallis tests were 
used, where appropriate, to compare serum vitamin D 
(25(OH)D and 1,25(OH)2D), percentage of participants 
displaying serum 25(OH)D ≥ 50 nmol/L and the percentage 
of hepatitis B vaccine responders across seasons. Independ-
ent t test, Chi square, one-way ANOVA and Kruskal–Wal-
lis tests were used, where appropriate, to compare demo-
graphic, anthropometric, alcohol and smoking use, sleep, 
mood, contraception use in women, ‘all-cause illnes’ data 
across seasons and between participants with serum 25(OH)
D ≥ 50 nmol/L and < 50 nmol/L. For study 2, Kruskal–Wal-
lis was used to compare the percentage of secondary hepa-
titis B vaccine responders after SSR, ORAL, SSR-P and 
ORAL-P. In addition, the percentage of secondary hepatitis 
B vaccine responders was compared between vitamin D 
supplementation (SSR and ORAL combined) and placebo 
groups (SSR-P and ORAL-P combined) using Chi square 
analysis. Serum 25(OH)D and 1,25(OH)2D were compared 
between vitamin D and placebo groups using mixed-model 
ANOVA (4 group (SSR, ORAL, SSR-P and ORAL-P) × 3 
time points (baseline, week 5 and 12) and 2 group (SSR and 
ORAL combined, SSR-P and ORAL-P) × 3 time points. 
Post hoc comparisons were conducted using Bonferroni cor-
rected t tests. Chi square tests were conducted to compare 
the percentage of participants displaying total serum 25(OH)
D ≥ 50 nmol/L at baseline, week 5 and week 12 between 
vitamin D and placebo groups. Independent samples t test, 
Mann–Whitney U and Chi square tests were used to com-
pare demographic, anthropometric, alcohol and smoking 
use, sleep, and mood data between vitamin D and placebo 
supplement groups. All statistical analyses were completed 




A total of 1103 men and women were recruited from June 
2014 to November 2015. Participants began the study 
throughout the year: 20% in winter (December–February), 
14% in spring (March–May), 26% in summer (June–August), 
and 40% in autumn (September–November). Participant 
flow, drop-out and exclusion before biochemical and statis-
tical analysis are summarized in Fig. 2. There was no signifi-
cant difference in demographics, anthropometrics, lifestyle 
behaviors, sleep, mood, contraception use, or all-cause ill-
ness between participants included and excluded in the final 
analysis (Supplemental Table 2).
Vitamin D and secondary hepatitis B vaccine response
At the time of the initial vaccination, 43% of participants 
had serum 25(OH)D < 50 nmol/L, 26% were vitamin D 
insufficient (serum 25(OH)D 30–50 nmol/L), and 17% were 
vitamin D deficient (serum 25(OH)D < 30 nmol/L). Only 
1 participant presented with severe vitamin D deficiency 
(serum 25(OH)D < 12.5 nmol/L). Fewer participants tended 
to respond to the hepatitis B vaccination who had 25(OH)
D < 50 nmol/L than those who were vitamin D sufficient at 
the time of initial vaccination (50% vs 58%, mean differ-
ence [95% confidence interval], − 8% [− 17%, 1%], P = 0.09, 
h = 0.16, Fig. 3a). Moreover, hepatitis B vaccine response 
was poorer in those with serum 25(OH)D ≤ 40  nmol/L 
(mean 30 ± 7 nmol/L) compared to participants with 25(OH)
D between 41 and 71 nmol/L (mean 56 ± 9 nmol/L) at the 
time of initial vaccination (mean difference [95% confidence 
interval], − 15% [− 26%, − 3%], P = 0.01, Fig. 3b). Fewer 
participants were also hepatitis B vaccine responders when 
they presented with low serum 1,25(OH)2D compared to 
participants who presented with high serum 1,25(OH)2D 
at the time of initial vaccination (50% vs 62%, mean dif-
ference [95% confidence interval], − 12% [− 24%, − 1%,], 
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P < 0.05, h = 0.24, Fig. 3c). Furthermore, fewer participants 
were hepatitis B vaccine responders when they presented 
with combined low 1,25(OH)2D and 25(OH)D compared to 
combined medium–high 25(OH)D and 1,25(OH)2D (43% 
vs 65%, mean difference [95% confidence interval], − 22% 
[− 39%, − 5%], P = 0.01). No differences were observed 
between those who presented with low serum 24,25(OH)
D compared to participants who presented with high serum 
24,25(OH)D at the time of initial vaccination (52% vs 60%, 
mean difference [95% confidence interval], − 8% [20%, 3%], 
P = 0.14).
There were no differences between participants with 
25(OH)D ≥ 50 nmol/L and < 50 nmol/L in demographics, 
anthropometrics, lifestyle behaviors, sleep, mood, contra-
ception use, or all-cause illness before the initial hepatitis B 
vaccination (Table 2). Anthropometrics, lifestyle behaviors, 
sleep, mood and all-cause illness also did not predict vaccine 
response (P > 0.05). Additionally, contraception use did not 
influence the vaccine response (P > 0.05, e.g., none vs oral 
contraception, 68% vs 62% mean difference [95% confidence 
interval], 6% [− 9, 21%]). Further regression analysis con-
trolling for BMI, smoking, alcohol, sleep and mood indicated 
that vitamin D-sufficient men, but not women, were 1.8 times 
more likely to be vaccine responders than those with serum 
25(OH)D < 50 nmol/L (OR [95% confidence interval], men 
1.8 [1.0, 3.2] and women 0.8 [0.4, 1.7]). Serum 25(OH)D, 
1,25(OH)2D, 24,25(OH)2D, vitamin D sufficiency and hepa-
titis B response were lower in men than women (P < 0.05, men 
vs women: 25(OH)D, 56 ± 30 vs 69 ± 32 nmol/L; 1,25(OH)2D, 
126 ± 32 vs 165 ± 43 pmol/L; 24,25(OH)2D, 4.4 ± 2.8 vs 
6.5 ± 3.7 nmol/L; vitamin D sufficiency, 49% vs 69%; hepatitis 
B response, 49% vs 65%).
Seasonal variation in vitamin D and hepatitis B vaccine 
response
Serum 25(OH)D, 1,25(OH)2D and vitamin D sufficiency 
(25(OH)D ≥ 50 nmol/L) were lower in winter than spring, 
summer and autumn (P < 0.05, Fig. 4a–c). In winter, 81% par-
ticipants had 25(OH)D < 50 nmol/L (Fig. 4b) with 32% of par-
ticipants vitamin D deficient (serum 25(OH)D < 30 nmol/L). 
The percentage of hepatitis B vaccine responders was also 
lower in winter than summer (44% vs 62%, mean difference 
[95% confidence interval], − 18% [− 31%, − 3%], P < 0.05, 
h = 0.36, Fig. 4d). With the exception of all-cause illness, 
participants recruited in the different seasons were similar 
as indicated by no differences in demographic, anthropomet-
rics, lifestyle behaviors, sleep, mood or use of contraception 
in women before the initial hepatitis B vaccination (Table 1). 
Similar seasonal variations in serum 24,25(OH)2D were also 
observed with winter serum 24,25(OH)2D contractions lower 
than summer and autumn (P < 0.05, winter 2.9 ± 2.2 nmol/L, 
spring 4.2 ± 2.8 nmol/L, summer 6.5 ± 3.2 nmol/L, autumn 
5.9 ± 3.4 nmol/L).
Fig. 2  Flow diagram indicat-
ing the numbers of partici-
pants assessed for eligibility, 
recruited, available at follow-up, 
and analyzed as part of Study 
1. Anti-HBs antibodies against 
hepatitis B antigen
Assessed for eligibility, n = 1268
Participants recruited, n = 1103
Follow-up blood sample, n = 679





<18 years of age, n = 108
Declined to participate, n = 57
Discontinued study, n = 424
(Withdrew from study, n = 302; 
Withdrew from army training, n = 22; 
Blood sample not given, n = 100)
Excluded from analysis, n = 232
(Atypical vaccination schedule, n = 193; 
Detectable baseline hepatitis B antibody
titres, n = 39)




Two hundred and thirty-one men were assigned to the inter-
ventions in January and February of 2016 and 2017. The 
study ended after reaching its scheduled date of closure. 
Participant flow, drop-out and exclusion before biochemi-
cal and statistical analysis are summarized in Fig. 5. There 
was no significant difference in demographics, anthropomet-
rics, lifestyle behaviors, sleep or mood between participants 
included and excluded in the final analysis (Supplemental 
Table 3). There were no adverse events reported relating to 
vitamin D or placebo supplementation. Participants were 
sufficiently blinded to the intervention since only 35% cor-
rectly guessed their allocated group, 30% were incorrect, and 
35% said they did not know whether they had received an 
active (SSR and ORAL) or placebo (SSR-P and ORAL-P) 
intervention.
The influence of low‑level simulated sunlight and oral 
vitamin  D3 on vitamin D status
At baseline, 75% of the volunteers had 25(OH)
D < 50 nmol/L, 45% were vitamin D insufficient (serum 
25(OH)D 30–50 nmol/L), and 30% were vitamin D defi-
cient (serum 25(OH)D < 30 nmol/L). Only 1 participant 
presented with severe vitamin D deficiency (serum 25(OH)
D < 12.5 nmol/L). There was no difference between vita-
min D and placebo supplementation groups’ demographics, 
anthropometrics, lifestyle behaviors, sleep, mood (Table 3), 
or vitamin D status (Fig. 6, P > 0.05). There were also no 
differences in these variables between combined vitamin D 
and placebo supplemented groups (Supplemental Table 4 
and Fig. 6). During the 12-week intervention, daily sun-
light exposure was low, as expected considering the lati-
tude and time of year [39], with similar sunlight exposure 
(0.22 ± 0.33 SED/day; P > 0.05) and dietary vitamin D 
intake (112 ± 84 IU/day, P > 0.05) in vitamin D and placebo 
supplement groups.
The vitamin D supplementation was successful in achiev-
ing vitamin D sufficiency and maintaining serum 25(OH)
D concentrations, so that at weeks, 5 and 12 serum 25(OH)
D concentrations in the vitamin D supplementation groups 
were higher than the placebo groups (P < 0.05, Fig. 6d). 
By week 5, 95% of participants in the vitamin D sup-
plementation groups were vitamin D sufficient (25(OH)
D ≥ 50 nmol/L, Fig. 6e). There was no difference in serum 
25(OH)D or percentage of participants achieving vita-
min D  sufficiency between vitamin D supplementation 
groups (P > 0.05). Serum 1,25(OH)2D was similar in all 
groups at baseline (P > 0.05) and increased with supple-
mentation (P < 0.05, Fig. 6f), with greater responses in the 
Fig. 3  Secondary hepatitis B vaccine response in those with serum 
25(OH)D < 50  nmol/L (n = 194) and serum 25(OH)D ≥ 50  nmol/L 
(n = 253 adults, (a), and low, medium and high serum 25(OH)
D (b), n = 447) and low, medium and high 1,25(OH)2D terciles (c), 
n = 444). †P < 0.1, lower percentage of secondary hepatitis B vaccina-
tion responders (anti-HBs ≥ 10 mIU/mL) in participants with 25(OH)
D < 50 nmol/L than vitamin D-sufficient participants. ‡P < 0.05, lower 
percentage of secondary hepatitis B vaccination responders (anti-
HBs ≥ 10  mIU/mL) in low 25(OH)D and 1,25(OH)2D terciles com-
pared to medium 25(OH)D and high serum 1,25(OH)2D terciles
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vitamin D supplementation groups compared to the pla-
cebo groups at week 5 (P < 0.05). There was no difference 
between groups at week 12 (P > 0.05) because 1,25(OH)2D 
increased from weeks 5 to 12 in placebo groups (P < 0.05). 
Serum 24,25(OH)2D responded similarly to supplementa-
tion as serum 25(OH)D, so that at weeks 5 and 12, serum 
24,25(OH)2D concentrations in the vitamin D supplementa-
tion groups were higher than the placebo groups (P < 0.05, 
Supplemental Table 5).
The influence of simulated sunlight and oral vitamin  D3 
on secondary hepatitis B vaccine response
Vitamin D supplementation beginning 3 days after the 
initial vaccination did not influence the secondary anti-
body response as the percentage of secondary hepatitis 
B vaccine responders was similar among the vitamin D 
and placebo groups (SSR 60%, SSR-P 57%, ORAL 56%, 
ORAL-P 52%, P > 0.05, Fig. 7a). Analyses comparing 
combined vitamin D to placebo also revealed no effect of 
Table 2  Study 1 baseline 
participant demographics, 
anthropometrics, lifestyle 
behaviors, sleep, mood and 
all-cause illness in those with 
serum 25(OH)D < 50 nmol/L 
and ≥ 50 nmol/L
Values presented as mean ± SD unless otherwise stated. There were no significant differences between vita-
min D sufficient  (25(OH)D  ≥ 50 nmol/L)  and those  participants  with 25(OH)D < 50 nmol/L in demo-
graphic, anthropometrics, lifestyle behaviors, sleep, mood or all-cause illness before the initial hepatitis B 
vaccination at baseline
COCP combined oral contraceptive pill, POP progesterone-only pill
a Female contraception data collected from a female specific questionnaire (n = 37 excluded from final data 
analysis)
b Greater scores indicate a greater feeling of the mood (maximum per mood = 20)
c Physician diagnosed cases of respiratory and gastrointestinal tract infection
Serum 25(OH)D
< 50 nmol/L n = 194 ≥ 50 nmol/L n = 253
Demographics
 Men [n (%)] 139 (72) 133 (53)
 Women [n (%)] 55 (28) 120 (47)
 Age (years) 21.3 ± 2.9 22.0 ± 3.2
 Ethnicity, Caucasian [n (%)] 186 (96) 248 (98)
Anthropometrics
 Height (m) 1.74 ± 0.08 1.71 ± 0.09
 Body mass (kg) 73.4 ± 10.8 70.1 ± 10.7
 BMI (kg/m2) 24.2 ± 2.8 23.9 ± 2.6
Lifestyle behaviors
 Alcohol user, [n (%)] 167 (86) 209 (83)
 Smoker, [n (%)] 122 (63) 137 (54)
Sleep night before initial vaccination
 Duration (h) 6.6 ± 0.7 6.3 ± 0.9
 Quality (very poor = 1 to very good = 4) 1.7 ± 0.7 1.7 ± 0.8
Contraception (n = 138)a
 None, [n (%)] 14 (33) 22 (23)
 COCP, [n (%)] 10 (23) 40 (43)
 POP, [n (%)] 2 (5) 7 (7)
 Injection, [n (%)] 4 (9) 4 (4)
 Implant, [n (%)] 13 (30) 22 (23)
Mood before initial  vaccinationb
 Vigor 8.4 ± 3.1 8.4 ± 3.0
 Anger 0.8 ± 1.4 0.9 ± 1.6
 Tension 4.7 ± 3.5 4.8 ± 3.3
 Confusion 2.5 ± 2.6 2.2 ± 2.3
 Depression 0.8 ± 1.8 0.7 ± 1.4
 Fatigue 4.2 ± 3.0 4.3 ± 3.0
All-cause illness [n (%)]c 29 (15) 42 (17)
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vitamin D supplementation on secondary hepatitis B vac-
cine response (SSR and ORAL vs SSR-P and ORAL-P, 
58% vs 54%, mean difference [95% confidence interval], 
4% [− 21%, 14%], P > 0.05, h = 0.08, Fig. 7b). Further-
more, a secondary analysis including only men who had 
25(OH)D < 50 nmol/L at baseline also revealed no effect 
of vitamin D supplementation on secondary hepatitis B 
vaccine response (P > 0.05).
Discussion
We determined the influence of vitamin D on the devel-
opment of the hepatitis B vaccination in healthy adults. In 
study 1, vitamin D status (25(OH)D and 1,25(OH)2D) at the 
time of initial vaccination influenced the subsequent second-
ary hepatitis B vaccine response: low vitamin D status was 
associated with poorer hepatitis B vaccine response (Fig. 3). 
Analysis controlling for demographic, anthropometric, and 
lifestyle factors revealed that vitamin D sufficient men, but 
not women, were nearly 2 times more likely to be respond-
ers to the hepatitis B vaccine than those with serum 25(OH)
D of < 50 nmol/L. These differences may be explained by 
lower serum 25(OH)D and 1,25(OH)2D in men and a lower 
proportion of men achieving vitamin D sufficiency com-
pared to women. Indeed, the hepatitis B vaccine response 
was poorer in men than women. Furthermore, hepatitis B 
vaccine response was associated with seasonal alterations 
in serum 25(OH)D and 1,25(OH)2D, with poorer hepatitis 
B vaccine responses in winter than summer (Fig. 4d). The 
findings of study 1 indicated a possible immunomodulatory 
role of vitamin D in the development of hepatitis B vaccine 
response. Given these findings, and the high prevalence of 
serum 25(OH)D < 50 nmol/L during winter (81% of persons 
had serum 25(OH)D < 50 nmol/L in study 1), in study 2 we 
examined the effect of winter vitamin D supplementation 
on hepatitis B vaccine response. Study 2, a randomized, pla-
cebo-controlled trial, involved a unique comparison of safe, 
simulated, casual skin sunlight exposure and oral vitamin 
 D3 supplementation specifically designed to achieve vita-
min D sufficiency. Contrary to our hypothesis, and despite 
achieving and maintaining IOM and EFSA defined vitamin 
D sufficiency in 95% of participants (Fig. 6), vitamin D 
supplementation beginning 3 days after the initial hepati-
tis B vaccination did not influence the hepatitis B vaccine 
response (Fig. 7).
The divergent findings of studies 1 and 2 are contrary to 
our hypothesis; however, they are consistent with animal 
and human studies that have identified it is the early (within 
24 h), rather than later, stages of orchestrating the develop-
ment of immunity that are most sensitive to intervention 
[40, 41]. Indeed, vitamin D, and specifically 1,25(OH)2D, 
may influence the hepatitis B vaccine response by stimu-
lating antigen presenting cells, which are pivotal for the 
Fig. 4  Seasonal variation in 
serum 25(OH)D (a), percentage 
of participants categorized as 
vitamin D sufficient (25(OH)
D ≥ 50 nmol/L; (b), serum 1, 
25(OH)2D (c), and percent-
age of secondary hepatitis B 
vaccination responders (anti-
HBs ≥ 10 mIU/mL; (d) in 447 
healthy, young men (n = 272) 
and women (n = 175) resid-
ing in the UK. a, c Data are 
mean ± SD. b, d Are percent-
ages represented by vertical 
bars. a Lower than summer 
(P < 0.05). b Lower than 
autumn (P < 0.05). c Lower than 
spring (P < 0.05)
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initial capturing, processing and presenting of the antigen 
at the site of vaccination [42, 43]. In animal models, it has 
been observed that locally produced 1,25(OH)2D induced 
migration of dendritic cells from the site of vaccination to 
non-draining lymphoid organs, where they can stimulate 
antigen-specific T and B cells to mount a strong and per-
sistent antibody response to diphtheria vaccination [7, 8]. 
Co-administration of 1,25(OH)2D with trivalent influenza 
vaccine in mice was shown to enhance both mucosal and 
systemic specific antibody response [44, 45], and highlights 
vitamin D as a potential vaccine adjuvant. In addition, pre-
vious research in humans has shown higher IgG antibodies 
in response to tetanus toxoid vaccination after 9 weeks of 
vitamin D supplementation compared to a placebo group 
[10], which lends further support to the notion of vitamin D 
as a potential adjuvant for vaccines more generally.
In both studies, we were unable to collect an additional 
blood sample after the third, and final, hepatitis B vaccine 
dose; therefore, it remains to be determined whether vita-
min D influences the final development of the hepatitis B 
vaccine response. As non-responders to initial vaccine dose 
tend to be poorer responders to subsequent doses [15], it is 
reasonable to hypothesize that persons low in vitamin D at 
the initial hepatitis B vaccination are more likely to be vac-
cine non-responders after the full hepatitis B vaccine course 
(Fig. 3). Future studies should, however, confirm the influ-
ence of vitamin D status at the time of initial vaccination 
on final antibody status after the full hepatitis B vaccine 
course. Study 1 was a prospective cohort study, and it is, 
SSR, n = 58
Discontinued 
intervention
Due to time commitment, 
n = 18
Excluded, n = 10
(<80% intervention 
compliance, n = 4; 
Atypical vaccination 
schedule, n = 2; 
Detectable baseline anti-
HBs, n = 4)
Assessed for eligibility, n = 434
Randomly assigned, n = 231
Declined to participate or 
excluded, n = 203
(Declined to participate, n = 73; Did 
not meet inclusion criteria, n = 19; 
Withdrew consent due to time 
commitment, n = 111)
Analyzed for secondary 
anti-HBs, n = 30
SSR-P, n = 52
Discontinued 
intervention
Due to time commitment, 
n = 16
Excluded, n = 8
(<80% intervention 
compliance, n = 4;
Atypical vaccination 
schedule, n = 2;
Detectable baseline anti-
HBs, n = 1; Indeterminate 
anti-HBs, n =1)
ORAL, n = 59
Discontinued 
intervention
Due to time commitment, 
n = 17
Excluded, n = 10
(<80% intervention 
compliance, n = 4; 
Atypical vaccination 
schedule, n = 4; 
Detectable baseline anti-
HBs, n = 1; Indeterminate 
anti-HBs, n =1)
ORAL-P, n = 62
Discontinued 
intervention
Due to time commitment, 
n = 22
Excluded, n = 11
(<80% intervention 
compliance, n = 7; 
Atypical vaccination 
schedule, n = 2; 
Detectable baseline anti-
HBs, n = 2)
Analyzed for secondary 
anti-HBs, n = 28
Analyzed for secondary 
anti-HBs, n = 32
Analyzed for secondary 




Fig. 5  CONSORT flow diagram indicating the numbers of partici-
pants assessed, recruited, randomly assigned, and analyzed as part 
of study 2. Anti-HBs antibodies against hepatitis B antigen, vita-
min D = SSR solar-simulated radiation, ORAL oral vitamin  D3, Pla-
cebo = SSR-P solar-simulated radiation placebo, ORAL-P oral pla-
cebo
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therefore, possible that factors other than vitamin D may 
explain the associations observed between vitamin D, season 
and the hepatitis B vaccine response. Previously, body mass 
index, mood, sleep and lifestyle (alcohol and smoking use) 
have been shown to influence the hepatitis B vaccination 
response [13–15]. Further, seasonal alterations in infectious 
disease and compromised host immunity might influence 
seasonal alterations in hepatitis B vaccination independent 
of vitamin D status [46]. A strength of our studies is that we 
took account of these factors and showed they were similar 
across the seasons (Table 1), and between persons who were 
vitamin D sufficient and not (Table 2), and supplementation 
groups (Table 3). Furthermore, all-cause illness, a marker of 
host immunity (Tables 1, 2), and living conditions were also 
similar. These similarities strengthen the argument that vita-
min D, rather than another factor, is responsible for observed 
association with hepatitis B vaccination in study 1. Nonethe-
less, future randomized control studies using similar supple-
mentation methods as study 2 that improve vitamin D status 
before the initial vaccination would verify whether vitamin 
D status at the time of initial vaccination is important in the 
development of the hepatitis B response.
The objective of these original studies was to explore the 
influence of vitamin D status on the hepatitis B vaccination 
response, with the interventions designed to achieve vita-
min D sufficiency including a 4-week period of low-level 
SSR (12 exposures) followed by 8 weeks of maintenance 
SSR (8 exposures). While vitamin D synthesis is the major 
established health benefit of UVR, the latter has immu-
nomodulatory (both suppressive and augmenting) effects, 
which may be mediated through vitamin D-dependent and 
-independent pathways [28, 29]. Thus, a previous human 
study of contrasting design examined for a possible effect of 
prior acute higher-level UVR exposure (UVB therapy lamps; 
daily exposures given at the individual’s sunburn threshold 
for 5 days) on the first hepatitis B vaccination response [47]. 
The investigators did not relate their findings to vitamin D 
status. They found no overall impact of UVR on cellular 
(lymphocyte stimulation test) or humoral (antibody titre) 
response to hepatitis B surface antigen, despite the UVR 
regime being adequate to reduce other immune responses, 
i.e., contact hypersensitivity and natural killer cell activity. 
Further analysis found individual difference in susceptibil-
ity, with a reduced vaccination response observed in those 
Table 3  Study 2 baseline participant demographics, anthropometrics, lifestyle behaviors, sleep and mood in solar-simulated radiation (SSR), 
SSR placebo (SSR-P) oral vitamin  D3 (ORAL) and oral placebo (ORAL-P) supplemented groups
Values presented as mean ± SD unless otherwise stated. There were no significant differences between supplemented groups in demographics, 
anthropometrics, lifestyle behaviors, sleep or mood before the initial hepatitis B vaccination at baseline (P > 0.05)
a Skin types are based on Fitzpatrick scale [31]
b Greater scores indicate a greater feeling of the mood (maximum per mood = 20)
SSR n = 30 SSR-P n = 28 ORAL n = 32 ORAL-P n = 29
Demographics
 Age (years) 21.5 ± 3.1 21.7 ± 3.4 20.9 ± 2.7 21.4 ± 3.0
 Ethnicity (Caucasian) [n (%)] 29 (97) 28 (100) 32 (100) 29 (100)
 Skin type (I, II, III, IV) [n (%)]a 3 (10), 8 (27),
14 (46), 5 (17)
2 (7), 10 (36),
13 (46), 3 (11)
3 (9), 11 (34),
13 (41), 5 (16)
2 (7), 9 (31),
15 (52), 3 (10)
Anthropometrics
 Height (m) 1.78 ± 0.05 1.77 ± 0.05 1.78 ± 0.07 1.78 ± 0.06
 Body mass (kg) 76.7 ± 11.6 76.8 ± 9.7 75.7 ± 12.3 77.5 ± 10.8
 BMI (kg/m2) 24.3 ± 3.3 24.4 ± 2.8 24.9 ± 2.8 24.9 ± 2.8
Lifestyle behaviors
 Alcohol user [n (%)] 23 (77) 22 (79) 26 (81) 23 (77)
 Smoker [n (%)] 17 (57) 16 (57) 17 (53) 11 (38)
Sleep night before initial vaccination
 Duration (h) 6.2 ± 0.8 5.9 ± 1.4 5.8 ± 1.5 5.8 ± 1.8
 Quality (very poor = 1 to very good = 4) 2.9 ± 0.7 2.8 ± 0.7 2.8 ± 0.7 2.8 ± 0.7
Mood before initial  vaccinationb
 Vigor 8.0 ± 3.4 9.0 ± 2.9 7.1 ± 2.9 8.2 ± 3.2
 Anger 1.0 ± 1.8 1.5 ± 2.5 1.2 ± 2.0 0.7 ± 1.6
 Tension 3.0 ± 2.2 3.6 ± 3.4 3.2 ± 3.3 2.6 ± 2.1
 Confusion 2.6 ± 3.2 2.5 ± 2.9 1.7 ± 2.1 1.5 ± 1.9
 Depression 0.7 ± 1.8 1.4 ± 2.7 0.6 ± 1.6 0.3 ± 0.6
 Fatigue 3.6 ± 2.7 4.9 ± 3.2 4.1 ± 3.5 4.1 ± 3.1
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individuals with a minor variant of IL-1beta polymorphism; 
prevalence of the variant is low and further studies are sug-
gested [48].
In combination with findings in elderly chronic kidney 
disease patients [11], our findings in healthy adults high-
light the potential importance of preventing low vitamin 
D status at the time of the initial vaccination for the ade-
quate development of the hepatitis B vaccination. Future 
research is merited to confirm the influence of vitamin D 
on the hepatitis B vaccination response in infants and the 
elderly, who are at greater risk of poor vitamin D status 
than healthy young adults [49], and because the hepatitis B 
Fig. 6  Serum 25(OH)D (a, d), percentage of participants categorized 
as vitamin D sufficient (serum 25(OH)D ≥ 50 nmol/L, (b, e), serum 
1,25(OH)2D c, f in response to 12 weeks of vitamin D supplementa-
tion by solar-simulated radiation (SSR) and oral vitamin  D3 (ORAL). 
a–c Show comparisons of individual vitamin D and placebo sup-
plementation groups (SSR, SSR-P, ORAL and ORAL-P). d–f Show 
combined vitamin D supplementation (SSR and ORAL) vs combined 
placebo (SSR-P and ORAL-P) groups. †P < 0.05, greater than base-
line. ‡P < 0.05, greater than week 5. *P < 0.05, greater than SSR-P. 
§P < 0.05, greater than ORAL-P. #P < 0.05, greater than combined 
SSR-P and ORAL-P. Data are mean ± SD (a, c, d f) and vertical bars 
represent percentages (b, e)
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vaccination is mandatory during infancy in several coun-
tries [21, 22]. This does not reduce the impact of the cur-
rent studies findings as many adults remain unvaccinated 
because childhood vaccine coverage is ~ 90% or less and 
routine infant hepatitis B vaccination began only recently 
in some countries (e.g., UK [21–23]). Adult vaccination 
is recommended for persons at increased risk of exposure 
to bodily fluids such as health care professionals, patients, 
and those traveling to areas of the world where hepatitis 
B is widespread, e.g., sub-Saharan Africa, east and south-
east Asia and the Pacific Islands [16]. The 1,25(OH)2D 
findings from study 1 also provide a mechanism by which 
maintaining vitamin D sufficiency and high 1,25(OH)2D 
may be important for vaccine immunogenicity beyond 
hepatitis B. As more than 50% fail to achieve vitamin D 
sufficiency during winter months [24–26], future research 
to further understand the role of vitamin D on vaccination 
more broadly is warranted. The 8% difference in hepatitis 
B vaccination response between people who were vitamin 
D sufficient and 25(OH)D < 50 nmol/L, and the 18% differ-
ence between winter and summer (Figs. 3a, 4d) are compa-
rable with the effects on the hepatitis B vaccine response 
shown for other lifestyle factors, e.g., smoking, obesity 
and poor sleep [13, 15]. Of particular clinical interest, the 
winter vaccine response (44% anti-HBs titers ≥ 10 mIU/
mL) was poorer than typically expected after two hepa-
titis B vaccine doses (50–90%: Fig. 4) [50]. Therefore, 
rather than restoring vitamin D sufficiency from its winter 
nadir, as in study 2, we suggest maintaining year-round 
vitamin D sufficiency, and where necessary preventing the 
decline in the end of summer serum 25(OH)D by com-
mencing vitamin D supplementation in late summer or 
early autumn and continuing until spring (~ 6 months). To 
maintain the end of summer serum 25(OH)D, individu-
als should aim to achieve current IOM and EFSA vitamin 
D dietary intake recommendations [19, 20]. We achieved 
this in study 2 with a daily 400 IU oral vitamin  D3 dose 
(Fig. 6). Oral vitamin  D3 supplementation is recommended 
in the autumn and winter because unlike simulated sun-
light, there is no time burden for an individual; no require-
ment for bulky irradiation cabinets; and oral vitamin  D3 
supplementation is effective regardless of sun reactive skin 
type [51]. Further, even very low sub-sunburn UVR doses 
were recently shown to cause skin cell DNA damage in 
easy-burning skin types [52]. Low-level sunlight expo-
sure, as used in study 2, may, however, provide benefits to 
human health in addition to vitamin D synthesis, and this 
is an active area of research [29].
Conclusions
In a prospective cohort study of 447 healthy adults (study 
1), vitamin D sufficiency was rare during the UK winter, 
and fewer people responded to the hepatitis B vaccina-
tion than during the summer. In study 1, poorer vitamin 
D status (serum 1,25(OH)2D ≤ 120 pmol/L and 25(OH)
D ≤ 40 nmol/L) at the time of initial vaccination was asso-
ciated with fewer healthy adults responding to the hepatitis 
B vaccine. In a subsequent randomized control trial (study 
2), vitamin D supplementation (oral or via simulated sun-
light exposure) that began 3 days after the initial vaccination, 
and achieved vitamin D sufficiency within 5 weeks, did not 
influence the hepatitis B vaccination response. Randomized 
control trials that manipulate vitamin D status before the 
Fig. 7  Percentage of participants categorized as secondary hepatitis 
B vaccine responders (anti-HBs ≥ 10 mIU/mL, (a, b) after 12 weeks 
of vitamin D supplementation by solar-simulated radiation (SSR) and 
oral vitamin  D3 (ORAL). a Compares individual vitamin D and pla-
cebo supplementation groups (SSR, SSR-P, ORAL and ORAL-P). b 
Shows combined vitamin D supplementation (SSR and ORAL) vs 
combined placebo (SSR-P and ORAL-P) groups. There was no dif-
ference in vaccine response between individual vitamin D and pla-
cebo supplementation groups (a SSR 60%, SSR-P 57%, ORAL 56%, 
ORAL-P 52%, P > 0.05) or between combined vitamin D and pla-
cebo groups (b SSR and ORAL 58% vs SSR-P and ORAL-P 54%, 
P > 0.05)
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initial vaccination are warranted to confirm the influence 
of vitamin D status at the time of initial vaccination on the 
hepatitis B vaccine response. In accordance with the find-
ings of the prospective cohort study (study 1), avoiding low 
vitamin D status at the time of the initial hepatitis B vaccina-
tion, by maintaining year-round vitamin D sufficiency, might 
be recommended to optimize the response to hepatitis B vac-
cination. This is particularly important for persons that rely 
on effective vaccination prophylaxis such as health care 
professionals and patients regularly exposed to bodily fluids.
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